ID   BB64-RCC
AC   CVCL_E907
SY   BB64 RCC; BB64; JAUP
DR   Wikidata; Q54795068
RX   PubMed=9637538;
RX   PubMed=10074909;
RX   PubMed=10661410;
RX   PubMed=15585611;
RX   PubMed=18698046;
CC   From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium.
CC   HLA typing: A*23,26; B*44,51; C*01,04 (PubMed=15585611).
CC   Derived from site: In situ; Kidney; UBERON=UBERON_0002113.
DI   NCIt; C9385; Renal cell carcinoma
DI   ORDO; Orphanet_217071; Renal cell carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_S693 ! BB64-EBV
SX   Sex unspecified
AG   Age unspecified
CA   Cancer cell line
DT   Created: 22-10-12; Last updated: 10-04-25; Version: 14
//
RX   PubMed=9637538; DOI=10.4049/jimmunol.160.12.6188;
RA   Gueguen M., Patard J.-J., Gaugler B., Brasseur F., Renauld J.-C.,
RA   Van Cangh P.J., Boon T., van den Eynde B.J.;
RT   "An antigen recognized by autologous CTLs on a human bladder
RT   carcinoma.";
RL   J. Immunol. 160:6188-6194(1998).
//
RX   PubMed=10074909; DOI=10.1002/(SICI)1097-0215(19990315)80:6<799::AID-IJC1>3.0.CO;2-U;
RA   Dumas F., Gala J.-L., Berteau P., Brasseur F., Eschwege P., Paradis V.,
RA   Lacour B., Philippe M., Loric S.;
RT   "Molecular expression of PSMA mRNA and protein in primary renal
RT   tumors.";
RL   Int. J. Cancer 80:799-803(1999).
//
RX   PubMed=10661410; DOI=10.1016/S1074-7613(00)80163-6;
RA   Morel S., Levy F., Burlet-Schiltz O., Brasseur F., Probst-Kepper M.,
RA   Peitrequin A.-L., Monsarrat B., Van Velthoven R., Cerottini J.-C.,
RA   Boon T., Gairin J.-E., van den Eynde B.J.;
RT   "Processing of some antigens by the standard proteasome but not by the
RT   immunoproteasome results in poor presentation by dendritic cells.";
RL   Immunity 12:107-117(2000).
//
RX   PubMed=15585611; DOI=10.1158/1078-0432.CCR-04-0072;
RA   Tykodi S.S., Warren E.H., Thompson J.A., Riddell S.R., Childs R.W.,
RA   Otterud B.E., Leppert M.F., Storb R., Sandmaier B.M.;
RT   "Allogeneic hematopoietic cell transplantation for metastatic renal
RT   cell carcinoma after nonmyeloablative conditioning: toxicity,
RT   clinical response, and immunological response to minor
RT   histocompatibility antigens.";
RL   Clin. Cancer Res. 10:7799-7811(2004).
//
RX   PubMed=18698046; DOI=10.1158/1078-0432.CCR-08-0028; PMCID=PMC2693478;
RA   Tykodi S.S., Fujii N., Vigneron N., Lu S.M., Mito J.K., Miranda M.X.,
RA   Chou J., Voong L.N., Thompson J.A., Sandmaier B.M., Cresswell P.,
RA   van den Eynde B.J., Riddell S.R., Warren E.H.;
RT   "C19orf48 encodes a minor histocompatibility antigen recognized by
RT   CD8+ cytotoxic T cells from renal cell carcinoma patients.";
RL   Clin. Cancer Res. 14:5260-5269(2008).
//